Quality Division Use Only

Scientific Area Committee (SAC): Chemistry/Instrumental Analysis **Subcommittee:** Seized Drugs

Standard/Guidelines Title E2329 - Standard Practice for Identification of Seized Drugs

Date added to OSAC Registry 8/7/2018

Can the Standard/Guidelines be followed in totality? Yes

Please explain if the Standard/Guidelines and the applicable clauses that cannot be followed in their totality:

This is an update to the previous OSAC conformance form signed on January 22, 2020 to declare that the Seized Drugs section is now fully compliant to ASTM standard E2329 after the successful validation of the Decision-Point assay method for cannabis plant substance material.

Prior to this validation, the Seized Drugs section couldn't adhere to clause 6.1.2 specific for cannabis plant substance identification. This was because on June 10, 2019, the House Bill 1325 changed the statutory definition of marihuana in the Texas Health and Safety Code Chapter 481.002.26 to exclude hemp as defined by Agriculture Code 121.001. The Agriculture Code and HB 1325 define hemp as the plant Cannabis Sativa L. with a delta-9 tetrahydrocannabinol (delta-9-THC) of not more than 0.3%. This legislation change required laboratories to demonstrate suspected marihuana samples to not only contain delta-9-tetrahydrocannabinol (THC) but also have a concentration greater than 0.3% to distinguish marihuana from hemp.

Compliance plan to achieve conformance to Standard/Guidelines:

Since the passage of the bill, the Seized Drug section compliance plan was to develop and validate a Decision-Point Assay method to be able to identify and determine whether the concentration of a substance, in this case delta-9-THC, is above or below a decision-point in plant material. Although legislation sets a 0.3% decision-point to distinguish marihuana from hemp, the "administrative decision-point" validated and used by this laboratory is at 1% or above. The laboratory "administrative decision-point" threshold was extended from the legislative decision point to encompass the variability in the assay procedure and to mitigate the risk of potential false positive results.

The section's procedure was updated on September 7, 2020 to incorporate this newly validated Decision-Point Assay method.

Declaration of Compliance to OSAC Registry Standard/Guidelines:

As of September 7, 2020, the Seized Drugs section is compliant with all requirements listed in "E2329 - Standard Practice for Identification of Seized Drugs".

Technical Leader:	N/A	**Date:**	N/A
Section Manager:	James T. Miller	**Date:**	09/16/2020
Division Director:	Amy Castillo Digitally signed by Amy Castillo Date: 2020.09.16 13:34:11 -05'00'	**Date:**	
Quality Director:	Erika Ziemak Digitally signed by Erika Ziemak Date: 2020.09.16 13:38:09 -05'00'	**Date:**	